Microalgal Bio-retinoid: A Retinol Alternative to Gently Rewind Signs of Photoaging

Algaktiv, a Barcelona-based cosmetic-actives maker, has spent several years growing, fractionating and liposome-encapsulating a strain of the microalgae Chlorella vulgaris to extract marine apocarotenoids from its xanthophyll pigments. The resulting ingredient, branded RetinART, is pitched to formulators as a way to get retinol-like results on collagen, pigmentation and cell turnover without the redness and peeling that send so many retinol users back to the shelf.

The concentration at which this gets tested matters more than the branding. In cell-based assays run by Algaktiv, a 1% dose of RetinART reduced melanin synthesis by 33%, compared with 9% for 0.15% retinol and 21% for 1% bakuchiol, according to figures the company has circulated through trade outlets including Personal Care Magazine. Cell proliferation rose 38% against 15% for retinol and 3% for bakuchiol, while collagen I and III increased 127% and 176% respectively. Those are striking numbers, but the participant counts, study duration and statistical significance behind them have not surfaced in the secondary coverage, which means the only way to weigh them properly is against the full dataset Algaktiv or its partners eventually publish.

That fuller dataset now exists, at least in part. Sánchez-Díez and colleagues published a peer-reviewed paper, "Bioretinoids from microalgae: Boosting retinol performance and tolerability," in the International Journal of Cosmetic Science this year, and the framing there is narrower than the marketing suggests. The microalgal bioretinoid performs best when co-formulated with retinol itself, improving hydration and cutting irritation relative to retinol alone, rather than standing in for retinol across the board. That is a meaningfully different formulation story: a booster that lets a brand keep retinol's actives but soften its side effects, not necessarily a wholesale swap.

Algaktiv's own explanation for the lower irritation centers on receptor selectivity. The company says conventional retinol activates RAR-alpha and RAR-gamma broadly, while RetinART is selective for RAR-beta, sidestepping the pathways it blames for irritation. Independent receptor pharmacology complicates that story. Published work has pointed to RAR-gamma, the dominant RAR subtype in skin, as the main driver of retinoid-induced irritation, and separate research on hairless mice found RAR-alpha-selective agonists carried reduced irritancy compared with pan-agonists that hit all three receptor subtypes. Whether RAR-beta selectivity is doing the mechanistic work Algaktiv describes, or whether it is a simplification of more tangled receptor biology, is not yet settled by data outside the company's own studies.

Formulators have a regulatory reason to pay attention regardless of how that mechanistic question resolves. The European Union's Regulation (EU) 2024/996, which took effect for enforcement on November 1, 2025, caps retinol, retinyl acetate and retinyl palmitate at 0.3% in leave-on and rinse-off products and 0.05% retinoic-acid equivalent in body lotions, and requires a "Contains Vitamin A" warning on labels. Non-compliant stock already on shelves has until May 1, 2027 to clear. A microalgal ingredient that is not itself a vitamin A derivative, and so falls outside that cap, gives brands a formulation route around a shrinking concentration ceiling rather than just a tolerability upgrade.

RetinART is not entering an empty field. Bakuchiol has held the retinol-alternative category for years, with market researchers at Future Market Insights and Custom Market Insights tracking a global bakuchiol market growing at roughly 14.86% annually, built on a reputation for gentleness that RetinART's own benchmarking data explicitly tries to beat on both pigmentation and collagen metrics. Algaktiv is positioning its ingredient as a third-generation entrant in a category that, until now, has really only had one serious incumbent.

What is still missing from the public record is a list of finished products actually formulated with RetinART at retail. The ingredient has cleared Cosmos certification and is distributed in some markets through Gelyma, a French marine-biotech supplier founded in 1997 that also sells its own algae-derived skin-revitalization line, Gelyol. That distribution relationship suggests Algaktiv is positioning RetinART as part of a broader pitch to brands looking for marine-sourced actives, not a single speculative launch. Whether formulators take Algaktiv's combination data to heart and start pairing RetinART with retinol at lower doses, or try to market it as a standalone 0.3%-cap workaround, will likely become clear only once the first finished goods reach shelves.